Tom Martin
Tom Martin is the director of post-acute care analytics at CarePort, powered by WellSky. He has led several data analytics teams providing insight to healthcare providers trying to improve quality of care for their post-acute care patients. He holds an M.S. in Resources Economics with a concentration in econometrics from the University of Massachusetts Amherst. As director of post-acute care analytics at CarePort, Tom studies how the ever-changing PAC regulatory and payment landscape is impacting care delivery and how acute and post-acute providers can leverage their data to improve patient care.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
MedCity News
How Microsoft can transform healthcare delivery
Microsoft’s latest eBook offers a look at how technology can help organizations meet patients’ changing expectations and provide personalized care.
Shares0
It’s been just over one year since the Covid-19 public health crisis took hold in the US and the crisis has transformed how providers deliver and, as importantly, how patients access care. Healthcare organizations demonstrated amazing resilience, agility and innovation to focus attention on how best to engage diverse patient populations, according to their preferences and needs, as well as how best to deliver care.
Healthcare organizations quickly turned to the power of the cloud to expand critical care and improve care continuum, all while minimizing exposure to risk for staff and patients. Connecting with the right patients at the right time is critical and technology is vital to helping care providers respond to the evolving demands while providing ac
The shift to home care: Another new normal resulting from Covid-19
Covid-19 has highlighted the critical importance of increased communication and transparency between acute and post-acute providers, and the immediate need for more diverse acute and post-acute care options.
Shares0
The Covid-19 pandemic has magnified critical issues in the United States healthcare system, and has made significant, potentially long-lasting impacts on care transitions, referral patterns and care delivery across the acute and post-acute settings. In what may be our new normal at the post-acute level, many hospitals, patients and families continue to opt for in-home care over institutional care settings such as skilled nursing facilities (SNFs). This marked shift in care delivery preferences can be explained by several factors, whether it’s a patient or family’s fear surrounding SNF stays during the Covid-19 pandemic, families that worry they will be restricted from visiting a patient in a SNF, o
Message :
Required fields AFM24 preclinical in vivo data will be presented as a poster Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 Affimed N.V. (Nasdaq: AFMD), a
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, announced today that preclinical
anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) )
AFM24 have been accepted for e-poster presentation at the American
Association for Cancer Research (AACR) Virtual Annual Meeting I, being
held on April 10-15. In addition, early data from a Phase 1 study evaluating AFM13 preloaded